Clypd grabs $19.4m Series B investment

Clypd, a sell-side technology provider for the television industry, has raised $19.4 million in a Series B round of funding led by RTL Group. Atlas Venture, Data Point Capital, Duke University, TiVo Inc., Transmedia Capital and Western Technology Investment all participated. The company has now raised $30 million in total. “clypd is one of the first companies to create a strong platform for programmatic sales for linear TV in the US. It offers a unique set of tools to the market at a crucial time, when programmatic video sales are growing rapidly,” said Rhys Noelke, Vice President Business Development at RTL Group. “clypd adds key TV sales competencies that will offer groundbreaking solutions for TV advertisers. We see great potential in the company – in both the US and Europe.”

Vulcun, a fantasy e-sports startup, has raised $12 million in funding from Sequoia Capital and other investors. The company allows players to win real money prizes based on picking fantasy teams made up on e-sports players. “We had no idea that in just 11 weeks we’d be receiving such an investment. I am deeply humbled and grateful to the community for making this possible and for making Vulcun the No. 1 place where they choose to play fantasy e-sports games,” co-founder Ali Moiz said in a statement.

ApplePie Capital, a marketplace lender for the franchise industry, has raised $6 million in Series A funding led by Signia Venture Partners, with participation from Freestyle Capital and QED Investors. The company has also secured more than $28 million debt capital commitments to fund franchise loans. “These milestones are a recognition of ApplePie Capital’s success and momentum in addressing the unique needs of the franchise industry, a market with an annual capital demand of $45 billion,” said CEO Denise Thomas.

Biotech company Edge Therapeutics has secured $72.5 million from two financing rounds. The most recent, a $56 million Series C-2 round, was led by Venrock with participation from Sofinnova Ventures, Janus Capital Management LLC, funds managed by Franklin Advisers, Inc., New Leaf Venture Partners and BioMed Ventures. The earlier $16.5 million Series C-1 round was completed in December last year. “This significant financing from a sophisticated syndicate of leading life sciences investors is a transformative event for Edge,” said Sol J. Barer, Ph.D., Chairman of the Board of Directors of Edge Therapeutics.